NCT Number: NCT06919133
The purpose of the MENTINA trial is to investigate the effect of using the smartphone-based MENTINA app for self-monitoring of depressive symptoms and rule-based feedback in individuals with current or previous depression, psychological vulnerability, and increased risk of depression in a randomized controlled trial (RCT) over a 12-month trial period. The aim is to potentially offer the MENTINA app as a self-management tool for individuals with psychological vulnerability and/or depressive symptoms or episodes.
Method and Design:
International, multicenter (three centers), parallel-group, RCT. The active group is assigned the smartphone-based MENTINA app including rule-based data feedback. The control group uses the MENTINA app for questionnaire-based data collection (outcomes) and collection of sensor-based data.
Study Procedures:
The trial will be open-label and unblinded. The trial uses the self-reported Patient Health Questionnaire-9 score (PHQ-9) as the primary outcome measure. Scoring will take place every 14 days over the 12-month trial period. Depressive symptoms during the first 6 months of app use will also be evaluated as secondary outcomes.
Participants, Including Inclusion and Exclusion Criteria A total of 220 individuals will be included from each center (Denmark, Germany, and Spain) with psychological vulnerability (depressive symptoms and possibly previous depressive episodes). A total sample size of 660 participants will be included.
Inclusion criteria:
* Age 18 years or older * Depressive symptoms, assessed by PHQ-9 > 8, AND/OR * Current or previous depressive episode(s) (ICD-10 F32, F33) * Owns and uses a smartphone * Signed informed consent to participate
Exclusion criteria:
* ICD-10 diagnosis of dementia, schizophrenia, mania, or bipolar disorder, as well as ongoing substance abuse * Current psychotic depression * Current suicide risk * Acute somatic illness requiring treatment (intensive care) * Insufficient language skills in Danish, German or Spanish (depending on site)
Side Effects, Risks, and Disadvantages
Side effects and risks:
We do not expect any serious side effects from using the MENTINA app. Possible side effects could include increased focus on one's own illness, potentially worsening depressive symptoms and suicidal thoughts.
Recruitment of Participants The study population will consist of adults vulnerable to mental health issues, defined by a PHQ-9 score > 8 or previous depressive symptoms at the time of inclusion. Each study site will be responsible for local recruitment and follow-up.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Psychiatric Center Copenhagen, Frederiksberg, Denmark
The intervention in the MENTINA trial consist of a smartphone app, which allows for daily monitoirng of symptoms such as mood, sleep, activity etc. Also, a library with content concerning depressive symptoms will be available.
Rules for feedback based of self-reported measures will be developed. Based on the self-reported measures participants will be suggested to read items from the library or call emergency health care facilities.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A smartphone-based app is developed and used in this trial. The smartphone-based MENTINA app allows for daily self-monitoring of depressive symptoms such as mood, sleep, activity etc and rule-based feedback based on self-monitored data as well as collected sensor data. Libary with relevant content will also be available and incoorporated in the rule-based feedback.
The MENTINA app is installed but no content and self-monitoring is available. No rule-based feedback. Only outcome measures can be done.
Time frame: From enrollment and during the study period of 12 months
Differences between the intervention group and the control group in the total Patient Health Questionnaire 9 items (PHQ-9) score performed every 14th day during the 12-months trial period.
Time frame: From enrollmetn to end of treatment af 12 months
Differences between the intervention group and the control group in the level of quality of life according to the WHO Quality of life BREF16 (WHO QoL)
Time frame: From enrollment to end of treatment at 12 months
Differences between the intervention group and the control group in the level of anxiety symptoms according to the Generalized Anxiety Disorder scale (GAD-7)
Time frame: From baseline and during the 12 months study period
Time frame: From baseline and during the 12 months study period
Differences between the group
Time frame: From baseline and during the 12 months study period
Number of healthcare contact during the study
Time frame: Form baseline and during the 12 months study period
Differences between the two groups
Time frame: From baseline and during the 12 months study period
Time frame: From baseline and during the study period
Usability of the app: System Usability Scale (SUS)
Time frame: From baseline and during the trial period
Qualitative interviews
Time frame: From baseline and during the trial period
Qualitative interviews on an subsample
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Other
The Effect of Digital Markers in the Self-management of Depressive Symptoms - The MENTINA Randomized Controlled Parallel Group Trial
Acronym: MENTINA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06951542
Behavior, Behavioral Symptoms
Mulanje, Malawi
View Trial DetailsNCT07064928
Acquired Immunodeficiency Syndrome, Behavior
Accra, Ghana
View Trial DetailsNCT07398040
Anxiety, Anxiety Disorders
Zaragoza, Spain
View Trial DetailsNCT06801925
Behavior, Behavioral Symptoms
London, United Kingdom
View Trial Details